Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vilaprisan - Bayer HealthCare Pharmaceuticals

X
Drug Profile

Vilaprisan - Bayer HealthCare Pharmaceuticals

Alternative Names: BAY 1002670; Bayer-sPRM; S-PRAnt; S-PRM; sPRM

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Antineoplastics; Antiprogestogens; Infertility therapies; Small molecules; Sulfones
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uterine leiomyoma
  • Phase II Endometriosis

Most Recent Events

  • 30 Jun 2022 Bayer terminates the phase III ASTEROID 4 trial in Uterine-leiomyoma in the US, Czech Republic, Japan, Russia and Ukraine due to a change in the development program (NCT03400956)
  • 06 Jun 2022 Bayer terminates the phase III ASTEROID 8 trial in Uterine leiomyoma in Japan due to changes in development plan of vilaprisan (PO) (NCT03476928)
  • 10 Nov 2021 Phase-III clinical trials in Uterine leiomyoma in United Kingdom, Taiwan, Spain, Sweden, Slovakia, Portugal, Poland, Norway, Netherlands, Lithuania, South Korea, Italy, Ireland, Germany, Denmark, Czech Republic, Canada, Bulgaria, Belgium and Australia (PO) (NCT03240523).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top